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Abstract
Background: Influenza and pneumococcal vaccination can prevent disease and potentially life-threatening
complications like sepsis. Elderly people have an increased risk of severe disease and therefore constitute a major
target group for vaccination. To increase vaccination coverage, targeted interventions are needed that take theory-
based specific determinants of vaccination behaviour into account. Moreover, message and campaign design
should consider specific age-related characteristics (e.g., information processing, media use). The aim of this study is
(i) to identify the specific informational and interventional needs of this risk group, (ii) to design and implement a
targeted intervention aiming to decrease vaccine hesitancy, increase vaccine uptake and decrease the health and
economic burden due to the respective diseases, and (iii) to measure the effect of this evidence-informed
intervention on various levels.
Methods: Prospective, multi-methods intervention study targeting individuals aged ≥60 years in a model region in
Germany (federal state of Thuringia, 500,000 inhabitants ≥60 years old). The development of the intervention
follows theory-based and evidence-informed principles: Data from a cross-sectional representative study provide
insights into specific determinants of the target group’s vaccination behaviour. Additionally, media use is analysed
to identify adequate communication channels for specific subgroups.
In pilot studies, the intervention materials are adapted to the specific cognitive requirements of the target group.
For development and implementation of the intervention, an interdisciplinary and trans-sectoral approach is used,
including psychology, communication science, design, medical science, epidemiology and various public health
players. The intervention will be implemented in autumn and winter 2017/18 and 2018/19 and adjusted in
between. Evaluation of the intervention includes: awareness, use and recall of intervention materials, effects on
changes in determinants of vaccination behaviour, self-reported vaccine uptake, and vaccination coverage in the
intervention area (primary outcomes), as well as disease incidences (secondary outcomes) and the economic
burden of influenza, pneumonia, invasive pneumococcal disease and sepsis for the healthcare system (tertiary
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outcomes).
Discussion: The data will add to the body of evidence on the effectiveness of evidence-informed vaccination
campaign development as well as on the clinical and economic effects of pneumococcal and influenza vaccination.
The effect of the intervention will teach valuable lessons about the principles of campaign development and
evaluation, and can motivate a subsequent nationwide intervention.
Trial registration: DRKS00012653. Registered 24.11.2017. Retrospectively registered.
Keywords: Influenza, Pneumococci, Pneumonia, Sepsis, Vaccine hesitancy, Targeting, Knowledge, Elderly, Cost
analysis, Implementation, Public health, Healthcare design
Background
Elderly people are at increased risk of acquiring or develop-
ing more severe courses of pneumococcal disease or influ-
enza, including complications like sepsis [1, 2]. Vaccines are
available that effectively reduce the burden of influenza and
pneumococcal diseases [3, 4] as well as severe complica-
tions like sepsis [5]. Additionally, it decreases hospital
length of stay and in-hospital mortality in patients with
these diseases [6–9]. The cost-effectiveness of influenza and
pneumococcal vaccinations has been shown by numerous
studies worldwide [10–14]. However, uptake remains low
within the general public [15] and the elderly population
[16–19], while incidence rates of severe manifestations like
sepsis are increasing [20]. In a recent resolution, the WHO
urges its member states to increase measures of sepsis pre-
vention to reduce the global burden of sepsis [21]. This
study protocol presents an interdisciplinary effort to design,
implement and evaluate an evidence-informed, complex
intervention [22] aiming to decrease vaccination coverage.
Specifically, the intervention aims to increase knowledge
about vaccination and diseases, influence determinants of
vaccination behaviour, increase self-reported vaccine uptake
and vaccine coverage in the intervention area (primary out-
comes) and decrease disease incidence of influenza, pneu-
monia, invasive pneumococcal disease and sepsis in the
target group (secondary outcomes). In order to evaluate the
intervention’s effectiveness these outcomes are compared
to (a) to the status quo ante, (b) to other federal states with-
out intervention and (c) in a quasi-experimental design be-
tween exposed and non-exposed parts of the intervention
population. Tertiary outcome is the potential reduction of
the economic burden of influenza, pneumonia and sepsis
for the healthcare system which will be assessed based on
health insurance claims data.
Influenza and pneumococcal vaccine hesitancy
In recent years, several studies and working group ef-
forts have analysed potential determinants of vaccine
hesitancy [23]. Vaccine hesitancy is defined as “(…) a
delay in acceptance or refusal of vaccination despite
availability of vaccination services. Vaccine hesitancy is
complex and context specific, varying across time, place
and vaccines” [24] (p. 4161). Reasons for vaccine hesi-
tancy are a lack of confidence (distrust in vaccinations
and the providing health system), complacency (underes-
timated risk of diseases or risk denialism) and/or incon-
venience (lacking or inconvenient access to vaccination)
[24]. The model was further extended by calculation
(engagement in an extensive information search for pros
and cons of vaccination) [25]. This factor explains the
fence-sitting effect: Individuals with high calculation
show extensive information search, ending up in a situ-
ation of insecurity and confusion about risks and bene-
fits, so that they are unable to decide and postpone their
vaccination decision into the future. Finally, people may
rely on herd immunity (factor collective responsibility).
In reference to theoretical frameworks, these reasons are
syndromes of psychological determinants of the vaccin-
ation decision [26].
A recent systematic review on influenza vaccine hesi-
tancy identified lack of confidence and complacency as
the most frequently reported barriers of influenza vac-
cine uptake in the elderly [27]. One reason for compla-
cency, for example, might be a lack of awareness about
sepsis as a severe complication of an infection. Studies
indeed show that sepsis, which is the most severe and
often-lethal complication of infections, remains largely
unknown in the public [28]. Given this situation, aware-
ness campaigns that address risk perceptions might be
able to effectively decrease influenza vaccine hesitancy.
In contrast to influenza vaccine hesitancy, there is only
minimal research addressing pneumococcal vaccine
hesitancy [16] and a review of interventions is lacking
[29]. Thorough knowledge about the determinants of
vaccine hesitancy as well as the target group, however, is
necessary for evidence-informed and targeted campaign
development [26, 30, 31].
The elderly as a target group
The elderly differ from the general public with regard to
their information processing [32, 33], risk perception [34],
decision quality [35] and media use [36, 37]. For example,
elderly individuals process gains and losses more ex-
tremely than younger individuals [38], they favour and
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remember positive over negative stimuli [39], they have
difficulties understanding available options in
decision-making [40] and show greater risk avoidance
[41]. Moreover, regarding media use elderly individuals
differ from their younger counterparts. Even though the
use of digital media increased constantly in people aged
≥60 years since 2012 [42], they use more traditional media
for health information (e.g., [43, 44]). Even though a num-
ber of intervention studies on influenza vaccine hesitancy
have been conducted for the described risk group of elderly
individuals (reviews: [23, 29]), none of the interventions ex-
plicitly took specific characteristics of cognitive ageing into
account. Therefore, this intervention will pay special atten-
tion to adapting the materials to the age group.
Transdisciplinary, evidence-informed campaign design
and evaluation
Health campaigns aim to change determinants of behav-
iour (such as knowledge, risk perceptions, attitudes) and
behaviour itself. Strategy-driven planning, implem-
entation and evaluation increase a campaign’s success
[30, 31, 45–47]. Communication science, social market-
ing and design experts have frequently highlighted the
importance of a precise analysis of the target group and
campaign setting [46, 48–50]. In this context, theories
and evidence from various disciplines are relevant, which
is why the present intervention takes a transdisciplinary
and multi-method approach. Epidemiological and med-
ical findings provide the necessary evidence to decide
which behaviours are suitable to promote health and
prevent diseases (e.g. vaccination as an effective measure
to prevent influenza infection). Theories and evidence
on health behaviour (social and health psychology) are
crucial in order to identify suitable intervention mes-
sages and strategies based on determinants of vaccin-
ation behaviour, e.g., risk perception. Evidence on
information processing and cognitive ageing (cognitive
and developmental psychology, design) allows adjust-
ment of materials to the cognitive preconditions of the
target group. Evidence regarding the effects of message
types (social psychology, communication science, design)
is needed to identify suitable message contents and st-
rategies. Evidence on media use, leisure activities and
values (communication, psychology, design) help to seg-
ment the target group [30, 51]. Finally, in order to evalu-
ate the intervention, the aforementioned disciplines
come into play again in order to assess primary cognitive
and behavioural outcomes (psychology, communication
science), mediating effects of media use on vaccination
coverage (design) and secondary outcomes such as re-
duction of disease incidence (epidemiology, medicine).
Moreover, to assess the reduction of the economic bur-
den as tertiary outcome, evidence and methods from
health economics are used. Thus, this study takes a
transdisciplinary multi-method approach using qualita-
tive and quantitative methods, experimental and non-ex-
perimental designs, as well as various sources of primary
and secondary data (e.g., surveys, health insurance
claims data). The evidence both from the literature and
the evidence created in this study will be harnessed to
design, improve and evaluate an intervention aiming to
decrease vaccine hesitancy, increase vaccine uptake and
decrease the health and economic burden due to the re-
spective diseases.
Status of the study at the time of submission
The status of the study is ongoing. The intervention has
two waves; the first wave is completed and evaluation is
currently underway. Evaluation has been completed re-
garding knowledge and attitudes; based on this, the inter-
vention is currently adapted for wave 2. Evaluations based
on data sources other than survey data are still pending.
Wave 2 will be implemented in Fall 2018; evaluation of
wave 2 will start in Winter 2018.
Methods
Study design and target population
In this intervention study, the population of the federal
state of Thuringia, Germany, aged 60 years and above,
forms the intervention group (N = 500,000). The inter-
vention will take place in two consecutive influenza sea-
sons (2017/18 and 2018/19, Fig. 1) and will be adapted
in between. Changes in the outcomes will be compared
to other German federal states and/or in a pre-post de-
sign depending on the outcome (specified below). Where
possible, the analyses will follow a two-step analysis, first
Fig. 1 Overview of the Vaccination60+ study
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with an overall evaluation of the age group over 60 in
general and then followed by analyses with special focus
on the age group that will be identified as the main tar-
get group of the intervention.
Development of the intervention: Inputs
The developmental process harnesses several sources of
data – besides thorough literature research a cross-sec-
tional representative survey identified determinants of
vaccination and profiled the target group for the strategic
planning process. The intervention is developed using a
User-Centred Design Approach (user-centred design ISO
13407, [52, 53]), supporting the criteria of usefulness, us-
ability and effectiveness. User-centred design involves fo-
cusing on the user’s needs, persona development, a
general task requirement analysis, carrying out and evalu-
ating early stage testing with the user group and follows
an iterative design-process.
Cross-sectional representative telephone survey
The data represent the base upon which the interven-
tion is developed and, at the same time, it represents
the benchmark against which the intervention’s success
will be evaluated.
Study population
n = 700, cross-sectional sample, representative for age over
60, rural/urban living areas, education. The sample size is
selected to obtain a similar sample sizes for pre- and
post-measurement. Because the post-measurement includes
a two-group comparison that requires a specific sample size
for statistical power justification of n for both surveys is
based on the post-measurement (see below: study popula-
tion in evaluation of the intervention). Dialling will be ran-
domized for Thuringia and data are collected anonymously.
Outcome measures
The full original questionnaire that shows the operatio-
nalisation of all measures is available via the Open Sci-
ence Framework (in German; [54]). The following
constructs were assessed:
Vaccine hesitancy
Syndromes of determinants for vaccination decision-making
(calculation, complacency, convenience, a lack of collective
responsibility and low confidence) were assessed with a
questionnaire tool based on previous work [26]. A long ver-
sion was used for influenza, for pneumococcal vaccine a
short version was created due to time constraints.
Further determinants of vaccination behaviour
These measures include multi-item batteries to assess (i)
knowledge about vaccines and vaccination [55] as well as
sepsis, (ii) attitude towards vaccination [56], (iii) perceived
risk of disease and vaccination [57], (iv) past experience
with influenza and previous vaccinations, (v) received rec-
ommendation by practitioners or healthcare workers. Fur-
thermore, we assessed modifying factors such as contextual
determinants (physicians’ reachability, travel time to the
physician, frequency of interaction with health service),
physical determinants (self-perceived health status, chronic
disease) and sociodemographic determinants (age, gender,
education, employment status, marital status, income, in-
surance status, town size and household situation).
Self-reported vaccine uptake and intention to vaccinate
Previous vaccination behaviour (influenza, pneumococ-
cal) was assessed.
Additional measures to support campaign design
Item-batteries assessed media use (conventional and new
media, apps), health information search behaviour [58] and
opinion leadership regarding health issues [59, 60], leisure
activities and interests as well as general values [61].
Statistical analyses
Multiple regressions to identify significant predictors of
self-reported vaccination behaviour, cluster analyses to
segment the target group, descriptive statistics to identify
relevant media channels. In telephone surveys item
non-response is common. We plan to analyse full cases
only, i.e., we use listwise deletion to deal with non-re-
sponse. However, we are aware that excluding missing
values via listwise deletion can (a) reduce the statistical
power of results and (b) induce bias if participants are not
missing completely at random (MCAR). Therefore, we
will only use listwise deletion if (a) the statistical power of
our analysis is not substantially reduced and if (b) we find
no signs for a violation of the MCAR condition. If one of
the conditions is violated multiple imputation will be used
to deal with missing values and imputed and non-imputed
results will be reported for a transparent comparison.
Vaccination uptake
Baseline of vaccination uptake (pneumococcal and influ-
enza vaccine coverage) according to age, gender and re-
gion are identified based on health insurance claims data
to specify target groups according to possible long-term
impact and efficacy.
Distribution of socio-demographic characteristics
Data from the Federal Statistical Office sources are ex-
amined regarding the target group’s distribution of edu-
cation, status of employment, family status, size of the
household, consumer panels, lifestyle values, income and
health insurance type.
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Persona development
Structured interviews are conducted with prototype in-
dividuals from the target group. Data from these qualita-
tive interviews are triangulated with all data sources
mentioned above to develop a female and male persona
as a reference point for ideation and development [62].
Touchpoint analyses
Potential touchpoints for the intervention (pharmacies,
physicians, leisure activities) and potential practical bar-
riers (distance to the physician) are assessed and decided
on the basis of relation of cost, reach and possible effi-
ciency for improved vaccination uptake in reference to
the persona and budget restrictions.
Experimental studies and specific pre-testing of materials
During the development phase, quantitative and qualita-
tive studies repeatedly explore the effects of the content,
design and materials. Individuals from the relevant age
group participate in these studies to take this target
group’s specific cognitive, emotional and motivational cha
racteristics into account (e.g., to test message types in the
target group, to pilot whether the target groups under-
stand and like the developed materials such as a website
or a flyer, to explore the effect of certain design elements).
The specific studies will be described elsewhere.
Implementation and dissemination: Activities
The intervention will be implemented from September
to February 2017/18 and 2018/19 (Fig. 1). The interven-
tion will be adapted based upon the evaluation results of
the first wave.
Dissemination
Multipliers Physicians, pharmacists and employers can
order free printed materials for dissemination. Other
multipliers can also order materials; however, these
former groups are the main multiplier groups.
Website A website is the richest information source of
the intervention (www.thueringen-impft.de). It addresses
all relevant reasons for vaccine hesitancy. All printed
materials relate to the website.
Out of home media and advertising Several advertise-
ments in special interest media and in outdoor areas will
be evenly distributed throughout the intervention region.
Flyers and posters (distributed at train stations and on
buses) as well as radio spots are used to increase the
visibility of the intervention, spread the slogan and at-
tract people to the intervention website.
Press coverage Press releases, interviews and reports
appear in print and online media as well as radio.
Tracking
In order to evaluate the impact of the different mate-
rials it will be necessary to track the distribution ways
of the materials. For the printed materials, there will be
an online ordering service, which allows tracking of the
location where the printed materials were ordered. On-
line tracking of a central intervention website will de-
liver further information about the regional access.
These sources will allow calculation of a correlation be-
tween the amount of distributed materials/frequency of
website use and vaccine uptake per sub-region. The
data will be stored according to current standards of
European law. Additionally, media monitoring allows
for tracking of media reports and their potential effect
on awareness and perception to control for external in-
fluences and contributes to reliability and validity of the
interventions’ evaluation.
Adaptation between intervention waves
First evaluation data will be available in early spring,
2018. In another representative study (see Primary out-
comes – Self-report data) we will assess awareness of the
intervention, assess which elements (e.g., flyer, website)
the participants saw, where they encountered the mate-
rials, which information they can remember and whether
it leads to changes in the primary outcomes. This allows
identifying elements that are related to changes in vac-
cine hesitancy and behaviour. Effective elements will be
used in the second wave (Autumn 2018), ineffective ones
will be omitted.
Evaluation of the intervention: Outcomes
The primary outcomes are indicators of vaccine hesi-
tancy as well as uptake rates of influenza and pne-
umococcal vaccination. Secondary outcomes are the
reduction of influenza, pneumonia, invasive pneumococ-
cal disease and sepsis incidence in the target group. As a
tertiary outcome the reduction of the economic burden
of influenza, pneumonia and sepsis for the healthcare
system will be assessed.
Primary outcomes – Self-report data
Hypotheses The intervention has an impact on the target
population’s vaccine hesitancy. In the course of the inter-
vention, mean vaccine hesitancy will decrease in the inter-
vention region as compared to the pre-intervention period.
This effect is expected to be driven by individuals who en-
countered the materials. Factors of hesitancy that have been
identified as especially relevant and that have been explicitly
addressed in the intervention design should show a greater
change than factors of vaccine hesitancy that have not been
addressed.
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Study population After each wave, a longitudinal panel
design will be applied. Participants (n = 700) will be sam-
pled in early December 2017 and after the second wave in
a similar manner. The sample will be representative of age
over 60, rural/urban living areas, and education. It is as-
sumed that half the population saw the intervention mate-
rials while half did not. The sample size was based on
a-priori power analysis (independent t-test: power 0.8, alpha
.05, effect size d = .2) and rounded to the nearest higher
hundred. The estimated effect size was informed by a re-
cent meta-analysis [63] on the effectiveness of health cam-
paigns in changing individuals’ knowledge.
Outcome measures The same measures for vaccine hesi-
tancy, further determinants of vaccination behaviour,
self-reported vaccination uptake, and socio-demographic
variables will be used as in the first representative study
(original questionnaire [54]). In order to successfully assess
the causal impact of the intervention materials on the out-
come measures, the representative cross-sectional surveys
will assess intervention exposure, i.e. whether participants
saw the materials and where; and if so, whether they re-
member certain elements and contents of the intervention
(e.g., flyer at the pharmacy, in a magazine, website, etc.).
Statistical analyses We will compare means by inspec-
tion of 95%CIs between exposed and non-exposed par-
ticipants regarding vaccine hesitancy measures and
self-reported vaccination behaviour. Changes in major
outcomes that have been specifically targeted by the
intervention (e.g., reduction of myths, increased percep-
tion of risk, increased knowledge of sepsis) will be
assessed as a function of being exposed. Among exposed
participants we will conduct regression analyses of be-
havioural change on the interaction with the different
intervention elements. We plan to analyse full cases only
i.e. we use listwise deletion to deal with non-response. If
conditions of listwise deletion (see above) are violated,
we will use multiple imputation.
Primary outcome – Vaccination coverage against influenza
and pneumococcus
Hypotheses The intervention has an impact on the vac-
cination uptake in the total target population. In the
course of the intervention the vaccination uptake will in-
crease compared to a pre-intervention period and neigh-
bouring federal states without intervention.
Study population The study population comprises a
sample of the statutory health-insured population in
Germany (~ 85%, with the remainder mainly being pri-
vately insured). Patients will be selected from health in-
surance claims data. These data are generated by all
statutory health insurance physicians for outpatient care
and regularly transmitted to their Association of Statu-
tory Health Insurance Physicians (ASHIP) as described
previously [64]. A subset of variables including (but not
limited to) birth date, sex, district of residence, type
and date of administered vaccinations, and diagnosis
data is transmitted on a quarterly basis to the Robert
Koch-Institute (RKI). The administrative regions of the
ASHIPs correspond to the federal states. Data is anon-
ymised and an individual patient identifier is created
allowing linkage of all the patient’s medical services to
the patient identifier. The data on vaccination status
and disease incidence is available for all statutory health
insured individuals in Thuringia. In Germany about
85% of the population are statutory health insured. For
the purpose of impfen60+ all individuals ≥60 years ful-
filling certain inclusion criteria will be included in the
cohorts. Retrospective analysis shows that for those
≥60 years, approximately 84% (ca. 560.000 individuals)
of the statutory health insured proportion in Germany
can be expected to be included per cohort. Hence,
power calculation is not regarded as useful.
Outcome measures Vaccination uptake among individ-
uals aged ≥60 years and in the relevant subgroup before
vs. after the intervention (2017, 2018, 2019) in Thuringia
vs. Eastern federal states without Thuringia vs. all other
federal states with available data.
Statistical analyses Different methodological approaches
will be considered to calculate vaccine uptake before
and after the intervention. First, coverage will be calcu-
lated as the proportion of patients vaccinated per year
(pneumococcus vaccination) or per season (influenza
vaccination). The denominator will be taken from the
KM6 statistics [65]. Second, vaccine uptake will be cal-
culated among selected patients in a cohort approach
[66]. Vaccine uptake will be calculated among those in-
dividuals who were < 60 years of age at the beginning of
the observation period and turn 60 thereafter (thus have
a new indication for the vaccine). For pneumococcus
vaccination only, vaccine uptake will also be calculated
for at-risk groups who have not been vaccinated in the
last 5 years before the respective calendar year of inter-
est and are thus recommended to receive the vaccine.
Vaccine uptake for both influenza and pneumococcus
will be analysed by age, district, year/season/month and
chronic underlying conditions (based on ICD-10 codes).
Secondary outcomes – Reduction of influenza, pneumonia,
invasive pneumococcal disease (IPD) and sepsis
These outcomes will be determined by means of differ-
ent methods and data sources to cross-validate the
results:
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a. Retrospective nationwide hospital discharge data-
base study,
b. Population-based registry study on bloodstream in-
fections in Thuringia,
c. Retrospective nationwide study based on Multidis-
ciplinary Quality Assurance in the Healthcare System
(SQG) data of community-acquired pneumonia,
d. Retrospective cohort study based on health insur-
ance claims data,
e. Retrospective study based on health insurance
claims data from Associations of Statutory Health Insur-
ance Physicians (ASHIPs).
Overall hypothesis If the primary outcome with in-
crease in vaccination rates in Thuringia is reached in the
elderly, we also expect a reduction in the incidence of
influenza, pneumococcal pneumonia, invasive pneumo-
coccal disease (IPD) and to a lesser extent sepsis and
pneumonia in the target population also.
a. Retrospective nationwide hospital discharge
database study.
Hypothesis. In comparison with other federal states,
the intervention region of Thuringia shows a
greater reduction and respectively lower increase in
incidence of influenza, pneumonia, IPD and sepsis.
Study population. A retrospective database study is
performed using state-wide hospital discharge data
from patients over the age of 60 regardless of their
vaccination status from 2014 to 2019 in the German
Diagnosis Related Groups (DRG) statistics, which
includes nearly complete inpatient billing data from
all general hospitals in Germany. All data provided
in the DRG statistics are anonymous. The DRG sta-
tistics is accessible by the Federal Statistical Office
via controlled remote data processing legally based
on the statistical data secrecy provision under sec-
tion 16 of the Federal Statistics Act (Bundesstatis-
tikgesetz). Each case contains a main diagnosis and
up to 89 secondary diagnoses, hospital mortality
and length of stay, procedures and patient demo-
graphics. We identify influenza, pneumonia, IPD
and sepsis in patients aged ≥60 years in Thuringia
(intervention group) and in the other 15 federal
states of Germany by a list of ICD-10 GM codes.
Cases with unknown age and gender will be ex-
cluded from analysis. As the data source for this
study includes nearly complete inpatient data from
nearly all acute-care hospitals in Germany (military
or prison hospitals are excluded), it practically cor-
responds to a population-based survey, hence power
calculations are not regarded as useful.
Outcome measures. We identify hospital-treated in-
fluenza, pneumonia, IPD and sepsis cases and
deaths in the period prior to and during the inter-
vention in Thuringia (2014–2016, 2017–2019) and
describe age- and sex-standardised incidence and
mortality rates for the Thuringian population as of
31 December, 2014. To evaluate the intervention ef-
fect, we will compare incidence and mortality rates
in Thuringia and the other federal states considering
further confounding factors as vaccination
behaviour.
Statistical analyses. Trends of age- and sex-
standardized incidence and mortality rates in the
years 2014–2019 will be compared between the
intervention group (population of the federal state
Thuringia) and the control group (population from
the other federal states). The data for analysis will
be complete, except for the excluded cases with un-
known age and gender (less than 0.002% expected);
hence no particular missing data handling is
necessary.
b. Population-based registry study on bloodstream
infections in Thuringia.
Hypothesis. The incidence of pneumococcal
bacteraemia among patients aged ≥60 years in
Thuringia will not increase further or will be
reduced during the intervention period compared
with the baseline measurement before intervention.
Study population. To further explore the burden of
IPD in Thuringia, we include all in- and outpatients
aged ≥60 years regardless of their vaccination status
with at least a single positive blood culture for
Streptococcus pneumoniae registered by
ALERTSNet between 1 October, 2014 and 1
October, 2019. ALERTSNet is a prospective
population-based registry for bloodstream infections
in Thuringia. ALERTSNet was initiated by funding
from the Federal Ministry of Health and land re-
sources in 2013, and aims to cover the whole of
Thuringia by 2018 Therefore, no power calculations
were performed as ALERTSNet aims to involve a
complete survey of a whole federal state and not a
sampling survey. All data obtained by ALERTSNet
are anonymous. Data by ALERTSNet are equally
protected from the access by unauthorized persons
as computer systems processing personal data in
the healthcare sector. Security measures include
that computer systems are physically protected
from unauthorized access and inlet and outlet com-
munication connections are protected by encryp-
tion according to current industrial standards.
Outcome measures. We identify proven cases of
pneumococcal bacteraemia and associated patient
data concerning age, sex and date of positive blood
culture in all patients aged ≥60 years recorded by
ALERTSNet since 1 October, 2014. As ALERTSNet
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currently does not cover all Thuringia (13.6% of
Thuringia in 2014, 32.6% of Thuringia in 2015, and
50.8% of Thuringia in 2016), the increasing
catchment areas have to be considered and
incidence rates have to be extrapolated during the
study period.
Statistical analyses. Mean changes in the incidence
and demographic data of patients with
pneumococcal bacteraemia will be compared in the
period prior to and during the intervention in
Thuringia (1/10/2014–30/09/2017 versus 1/10/
2017–30/09/2019). As there is no other
population-based registry for bloodstream infec-
tions in Germany, no direct comparison to an-
other federal state is possible. Although missing
data might be possible for demographic data,
they are not expected for the main outcome inci-
dence (defined by the number of cases and date
of positive blood culture for S. pneumoniae).
Therefore, all patients reported by ALERTSNet
≥60 years with pneumococcal bacteraemia will be
included in the analysis. Currently, retrospective
analysis of proven cases of pneumococcal bacter-
aemia in Thuringia by ALERTSNet from 1 Octo-
ber 2014 to 30 September 2016 is completed and
first prospective data for the period of 1 October
2016 to 30 September 2017 are available.
c. Retrospective nationwide study based on
Multidisciplinary Quality Assurance in the
Healthcare System (SQG) data of community-
acquired pneumonia.
Hypothesis. In comparison to the whole of Germany
the intervention region of Thuringia shows a
greater reduction and respectively lower increase in
incidence rates and mortality rates of inpatients
with community-acquired pneumonia.
Study population. To assess the incidence rates of
hospital-treated community-acquired pneumonia,
retrospective data published by the Multidiscip-
linary Quality Assurance in the Healthcare Sys-
tem (SQG) will be used. As community-acquired
pneumonia belongs to the services for the exter-
nal inpatient quality assurance requiring docu-
mentation in Germany since 2005, data on age,
sex, hospitalisation, severity of disease and in-
hospital mortality rate among patients with
community-acquired pneumonia will be obtained
annually by the responsible quality department of
SQG of Thuringia and all of Germany starting in
2014. All annual data published by SQG are an-
onymous and available with a delay of 7 to
8 months in the subsequent year. For a
population-based study power calculations are
not regarded as useful.
Outcome measures. We identify incidence rates and
in-hospital mortality rates of inpatients with
community-acquired pneumonia for different age
groups aged ≥60 years (60–69 years, 70–79 years,
80–89 years) and assess the severity of disease (dis-
tribution of CRB-65 score) [67] in the period prior
to and during the intervention in Thuringia (2014–
2016, 2017–2019) compared to all of Germany.
Statistical analyses. Trends of age-specific annual
incidence rates and in-hospital mortality rates of
hospital-treated community-acquired pneumonia
for age groups 60–69 years, 70–79 years and 80–
89 years and mean changes of CRB-65 score will be
compared between the intervention region Thurin-
gia and all of Germany in the years 2014–2019. As
SQG reports completeness of data in 100%, no
missing data have to be considered. Currently,
retrospective data published by SQG for hospital-
treated community-acquired pneumonia are avail-
able for the years 2014, 2015 and 2016.
d. Retrospective cohort study based on health insurance
claims data.
Hypothesis. The incidences of influenza, pneumonia,
IPD and sepsis are lower in people vaccinated than
non-vaccinated over 60 years of age.
Study population. To quantify the impact of
influenza and pneumococcal vaccination on
influenza, pneumonia, IPD and sepsis incidence and
outcomes, a retrospective database study will be
performed including about 300,000 persons
≥60 years, living in Thuringia, who are insured with
one of the largest statutory health insurances in
Germany (AOK PLUS, insured persons form about
40% of the Thuringian population). The exposed
cohort group is expected to consist of about
130,000 patients with pneumococcal and/or
influenza vaccination in 2014; the unexposed
cohort group are patients without pneumococcal
vaccination in 2008–2017 and without influenza
vaccination in 2012–2017. The observation period
covers the years from 2015 to 2017. The study is
partly retrospective (2008–2016) and partly
prospective (2017). The study was designed in
2017 and we have commenced in 2017 to
acquire the data from 2008 to 2016 which are
available from German SHIs with a regular delay
of 9–12 months, so that the earliest time a SHI
can transfer 2016 data is the end of 2017. Data
preparation for statistical analysis has just begun
and will not be finished before the end of 2018.
As the inclusion of patients of 60 years and
above in Thuringia insured with the SHI AOK
PLUS practically corresponds to a complete
survey, power calculations are not regarded as
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useful. All routine data collected by health
insurances are anonymous.
Outcome measures. Incidence rates and hospital/
ICU admission rates of influenza, invasive
pneumococcal diseases, pneumonia and sepsis, as
well as in-hospital and long-term mortality will be
compared between vaccinated and unvaccinated
persons.
Statistical analyses. Retrospective cohort study
using adequate adjustment methods (multiple
regression analysis, propensity score matching). The
data for analysis will be complete; hence no
particular missing data handling is necessary.
e. Retrospective study based on health insurance
claims data from Associations of Statutory Health
Insurance Physicians (ASHIPs).
Hypothesis. If the vaccination uptake increases
considerably, related disease incidences will
subsequently decrease.
Study population. See above under primary
outcome, vaccination rate.
Outcome measures. Disease incidences for influenza
and pneumococcal diseases among individuals aged
≥60 and in a to be determined subgroup of
individuals before vs. after the intervention (2017
- 2019) will be compared in Thuringia vs. outside
Thuringia as a function of vaccination uptake.
Statistical analyses. The health insurance claims
data include ICD-10 codes assigned by the physi-
cians specifically for influenza and pneumococcal
diseases and disease-related unspecific clinical syn-
dromes. A number of ICD-10 codes that represent
the clinical syndromes acute-respiratory infection
and influenza-like illness will be selected. For
pneumococcal diseases, ICD-10 codes for
community-acquired pneumonia and invasive
pneumococcal disease will be selected. The data for
analysis will be complete; hence no particular miss-
ing data handling is necessary.
The ICD-10 codes will undergo a data cleaning pro-
cedure so that they represent the specific endpoints
most accurately. The disease incidence will be calcu-
lated as the proportion of diseased patients per year
(pneumococcal disease) or per season (influenza dis-
ease, third and fourth quarter of calendar year plus
first quarter of the subsequent year). The denomin-
ator will be taken from the statistics of statutory
health insurances [65]. All routine data collected by
health insurances and ASHIPs are anonymous.
Tertiary outcomes – Reduction of economic burden
Hypotheses Vaccinated patients show lower healthcare
utilisation, costs and sick-leave days than non-vaccinated
patients.
Study population (The study population is identical to
secondary outcomes, section d.) 300,000 persons
≥60 years, living in Thuringia, who are insured in the
AOK PLUS. The exposed cohort group is expected to
consist of about 130,000 patients with pneumococcal
and/or influenza vaccination in 2014; the unexposed co-
hort group are patients without pneumococcal vaccin-
ation in 2008–2017 and without influenza vaccination in
2012–2017. The observation period covers the years
2015 to 2017. We use real-world claims data to deter-
mine resource utilisation and costs across all sectors of
medical care. A social health insurance (SHI) perspective
is adopted. All routine data collected by health insur-
ances are anonymous.
Outcome measures Mean differences between exposed
and unexposed persons in healthcare costs and resource
utilisation including hospital care, rehabilitation, out-
patient visits, medication, remedies, therapeutic aids,
nursing care as well as sick-leave days, followed up at in-
tervals of 1, 2 and 3 years.
Statistical analyses Retrospective cohort study using
adequate adjustment methods (multiple regression ana-
lysis, propensity score matching). The data for analysis
will be complete; hence no particular missing data hand-
ling is necessary.
Discussion
This project is part of the trans-sectoral InfectCon-
trol2020 consortium, hosted by the Leibniz Institute for
Natural Product Research and Infection Biology e. V.
The consortium is concerned with the “rapidly increas-
ing threat…arising from new or resistant pathogen-
s….This threat is further afflicted by a drastic lack of
(new) effective drugs as well as insufficient preventive
and diagnostic possibilities” (http://www.infectcon-
trol.de/de/english.html). Vaccination is an effective
measure to prevent infections and subsequently – by re-
ducing the number of infections – also the use of antibi-
otics and severe consequences such as sepsis. Moreover,
decreasing use of antibiotics can reduce the develop-
ment and spread of antimicrobial resistance [68]. With
this study we add to the consortium’s goals of finding
new methods of infection-prevention by providing add-
itional behavioural insights about vaccine hesitancy re-
garding influenza and pneumococcal vaccine in the
elderly and about evidence-informed vaccination inter-
vention design and evaluation.
The study offers unique learning opportunities for
theory-based and evidence-informed intervention devel-
opment and evaluation. Firstly, it uses a theoretical
model of vaccine hesitancy to assess the underlying rea-
sons for vaccine hesitancy that are addressed by the
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intervention. Using theory-based approaches has been
shown to increase the success of interventions [69],
however, in the field of vaccination advocacy there is a
lack of theory-based interventions [70]. Additionally,
this study also explicitly takes processes of cognitive
ageing into account and applies a user-centred design
approach. Secondly, triangulation and integration of
diverse types and sources of data to target and evalu-
ate the intervention will provide rich insights into the
processes of behavioural change, user-centred design
approaches as well as future promising principles of
vaccine advocacy. Thirdly, the evaluation of the in-
tervention on several levels (hesitancy, behaviour, disease
and economic burden) allows for comparing and
cross-validating results from different sources, which cre-
ates insights for future evaluation processes. It also allows
identification of the challenges, benefits and pitfalls of the
respective data sources (e.g., the national monitoring of
disease incidences with data from health insurance refund
claims is piloted and evaluated).
An additional goal of the intervention is to educate
about sepsis as a severe consequence of infections. This
is another innovative aspect of this project. WHO has
recently recognised the importance of preventing sepsis
by acknowledging a new resolution [21]. This study will
show whether an increase in knowledge was obtained
with the intervention and whether knowing more about
sepsis decreases vaccine hesitancy and increases vaccin-
ation behaviour.
Moreover, the use of different data sources allows a
pathogen-specific (influenza, invasive pneumococcal dis-
ease) and syndrome-specific (pneumonia, sepsis) evalu-
ation of the reduction of vaccine-preventable diseases
(secondary outcome).
Finally, the study expands real-world, data-based evi-
dence on the relationship between vaccination uptake
and clinical and economic burden of disease (influenza,
pneumonia, IPD and sepsis).
Generalisability and adaptability of the specific inter-
vention to other federal states in Germany will depend
on how similar the target group’s characteristics and de-
terminants of vaccination are to other federal states. As-
suming similar reasons of vaccine hesitancy, the content
of the intervention is suitable for other federal states,
too. Assuming, on the contrary, that characteristics dif-
fer, such as reasons for vaccine hesitancy, lifestyle or
values, specific distribution channels and visual key ele-
ments need to be adapted.
Due to the multi-methods and multi-data sources
approach for intervention evaluation the results will be
multifaceted, too. While this creates unique oppor-
tunities, it also comes with considerable challenges: data
may sometimes be difficult to compare. Furthermore, lim-
itations of the individual data sources are the following:
– Microbiological diagnostics of the secondary
outcome pneumonia is not standardised between
German hospitals.
– Although ALERTSNet aims to cover all of
Thuringia, it only covers specific centres at certain
times.
– ICD codes used by the German DRG statistics are
considered to have high specificity, but only
moderate sensitivity, thus being prone to an
underestimation of disease prevalence, e.g., for sepsis
by up to 3.5-fold [71, 72].
– Results from cohort studies assessing the impact of
vaccination on disease incidences or resource
utilisation might be subject to confounding by
indication or healthy vaccinee bias. However,
relevant covariates will be collected and adjusted
analyses will be performed to mitigate this risk.
– Awareness for the intervention could be so low that
stratifying data per material or source of
information might be difficult. If awareness is below
50% in the first 100 participants of the
representative study after wave one, participants
with awareness for the intervention will be
oversampled to reach a sample of at least n = 350
participants per group. Otherwise, reliable statistical
analyses about the effects of the single aspects of the
intervention will be not possible.
The intervention is limited to two seasons and an ob-
servation period before and after each launch. Some ef-
fects of the intervention may only become apparent
after a longer period of time and will thus be missed due
to the limited duration of the observation.
In sum, this study will add further knowledge to
theory-based and evidence-informed development of in-
terventions based on the assessment of relevant behav-
ioural determinants within the target group. Lessons
learned from this project can have an additional positive
impact on campaign development especially for the
growing 60+ age group for various other health behav-
iours (e.g., healthy diets, physical activity, age-related
prevention campaigns such as screenings). The study
uses a sophisticated and multi-faceted approach to
evaluation, which can identify chances and pitfalls of
several data sources. It could therefore serve as a bench-
mark for future evaluation studies.
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